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Abstract
Objective: Autosomal-dominant familial Alzheimer disease (AD) is caused by
by variants in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precur-
sor protein (APP). Previously, we reported a rare PSEN2 frameshift variant in
an early-onset AD case (PSEN2 p.K115Efs*11). In this study, we characterize a
second family with the same variant and analyze cellular transcripts from both
patient fibroblasts and brain lysates. Methods: We combined genomic, neu-
ropathological, clinical, and molecular techniques to characterize the PSEN2
K115Efs*11 variant in two families. Results: Neuropathological and clinical
evaluation confirmed the AD diagnosis in two individuals carrying the PSEN2
K115Efs*11 variant. A truncated transcript from the variant allele is detectable
in patient fibroblasts while levels of wild-type PSEN2 transcript and protein are
reduced compared to controls. Functional studies to assess biological conse-
quences of the variant demonstrated that PSEN2 K115Efs*11 fibroblasts secrete
less Ab1–40 compared to controls, indicating abnormal c-secretase activity. Anal-
ysis of PSEN2 transcript levels in brain tissue revealed alternatively spliced
PSEN2 products in patient brain as well as in sporadic AD and age-matched
control brain. Interpretation: These data suggest that PSEN2 K115Efs*11 is a
likely pathogenic variant associated with AD. We uncovered novel PSEN2 alter-
native transcripts in addition to previously reported PSEN2 splice isoforms
associated with sporadic AD. In the context of a frameshift, these alternative
transcripts return to the canonical reading frame with potential to generate
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deleterious protein products. Our findings suggest novel potential mechanisms
by which PSEN variants may influence AD pathogenesis, highlighting the com-
plexity underlying genetic contribution to disease risk.
Introduction
Autosomal-dominant familial Alzheimer disease (FAD) is
caused by heterozygous variants in presenilin 1 (PSEN1),
presenilin 2 (PSEN2), or amyloid precursor protein
(APP).1 While earlier in onset, FAD is clinically and neu-
ropathologically similar to the more common later onset
“sporadic” form of AD. Thus, studying FAD contributes
to understanding pathogenic mechanisms relevant to both
Mendelian and complex sporadic AD.2 To date, hundreds
of PSEN variants have been reported and the vast major-
ity are missense changes.3 Presenilin protein (PS) forms
the catalytic component of the transmembrane c-secretase
complex to process over 100 substrates including APP.4
FAD-associated PSEN variants are hypothesized to alter
the c-secretase processing of APP, producing species of
amyloid beta (Ab) of varying solubility and aggregation
potential that can be identified in amyloid plaques, a
defining neuropathological feature of AD.5 How PSEN
variants lead to FAD is uncertain; controversy remains
regarding the relative importance of a gain-of-function
impact of PSEN variant by alteration of the quality of Ab
species and Ab42:40 ratios versus deleterious loss-of-func-
tion consequences of variants.6–8
In 2010, we reported the first case of a PSEN2 two
base-pair deletion, PSEN2 c.342_343delGA, p.K115Efs*11,
identified in an early-onset AD case, suggesting this novel
PSEN2 variant may be a pathogenic cause of FAD.9 The
patient was diagnosed with AD at age 56 years but there
was limited family history information to determine seg-
regation in an autosomal-dominant inheritance pattern.
Despite the early-onset of disease and in silico analysis
suggesting pathogenicity, PSEN2 K115Efs*11 (PSEN2
K115fs) remained a variant of unknown significance given
the unique presentation in one case.
Using targeted exome screening, we analyzed 135
archived samples from a cohort of early-onset familial AD
cases at the University of Washington for known demen-
tia genes, including PSEN1, PSEN2, and APP. During this
study, we identified a second early-onset AD individual
who also carried the PSEN2 K115fs variant.
We present here clinical and neuropathological data
from two early-onset AD individuals carrying the PSEN2
K115fs variant whose families are not known to be related
and are from distinct regions in the United States. We
describe the clinical and neuropathological features of
members in both families. We identified a novel splice
isoform in PSEN2 K115fs patient brain lysate that was
not readily detected in patient fibroblasts. PSEN2 K115fs
patient-derived alternative splice isoforms are predicted
to remain in frame, potentially generating a protein with
large structural differences that could alter PS2 function
and drive AD pathologic processes. Collectively, these
data further support pathogenicity of this unusual vari-




Skin punch biopsies (3 mm) were obtained from all sub-
jects giving informed consent under protocols approved by
the University of Washington (UW) Institutional Review
Board. Age-matched control lines were obtained from the
UW Alzheimer Disease Research Center (ADRC). The
PSEN2 K115fs (Family B proband) skin sample was
obtained under an ADRC-affiliated UW Institutional
Review Board approved protocol. Fibroblast lines were pre-
pared either through the ADRC or University of Washing-
ton Cytology laboratory. Cell lines were maintained in
fibroblast culture media (Dulbecco’s Modified Eagle Med-
ium [DMEM] supplemented with 10% fetal calf serum, 1%
L-glutamine, 0.1% penicillin/streptomycin), and fibroblast
lines from passage numbers 5 to 15 were used for experi-
ments.
Neuropathology
The study was approved by the UW IRB; neuropathology
diagnostic protocols aligned with NIA-AA guidelines.10–14
Sections (5 lm) were prepared from formalin-fixed,
paraffin-embedded sections, and histochemically stained
for hematoxylin and eosin with Luxol fast blue and
Bielschowsky, and immunohistochemistry using a Leica
Bond III Autostainer (Leica Bio-Systems, Richmond, IL,
USA) for paired helical filament tau (PHF-tau) (mouse,
AT8, 1:1000, Pierce, Rockfield, IL, USA), phospho-tau
(mouse, Tau 2, 1:1000, Sigma-Aldrich, St. Louis, MO,
USA), Ab (6E10) (mouse, 1:5000, Covance, Burlington, NC,
USA), phosphorylated TDP-43 (pTDP43) (rat, ser409/
ser410, 1:1000, Millipore, Burlington, MA, USA), a-synu-
clein (LB509, mouse, 1:500, Invitrogen, Carlsbad, CA, USA),
GFAP (rabbit, 1:2000, DAKO, Santa Clara, CA, USA),
and IBA-1 (rabbit, 1:1700, Wako, Richmond, VA,
USA) with appropriate secondary antibody staining.
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Molecular genetics
Exome sequencing
Libraries were constructed according to an optimized
protocol developed by the UW Medicine Center for Pre-
cision Diagnostics and Northwest Clinical Genomics Lab-
oratory. Sample-specific fragment libraries were prepared
using the KAPA Hyper Prep DNA library kit (KAPA
Biosystems, Wilmington, MA, USA) and subsequently
enriched with the xGen Exome Research Panel v1.0 (Inte-
grated DNA Technologies, Coralvilla, IA, USA). The stan-
dard off-the-shelf probe set was supplemented with baits
to capture missing targets, and boost coverage of poorly
covered targets. Paired-end sequencing of the exome-
enriched libraries was performed on a HiSeq 4000 instru-
ment (Illumina, San Diego, CA, USA) according to the
manufacturer’s protocol.
Sanger sequencing
Primers based on the GRCh37/hg19 (February 2009) ver-
sion of the human genome sequence were used to amplify
a region containing the PSEN2 K115Efs*11 region
(Table 2). Polymerase chain reaction (PCR)-amplified
fragments were sequenced using standard dye-terminator
chemistry and separated on an ABI 3500 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Resulting
traces were analyzed using Mutation Surveyor v5.0
(SoftGenetics, State College, PA, USA).
Three-dimensional quant studio dPCR
Digital PCR (dPCR) allows accurate quantification of
nucleic acid templates by partitioning the PCR reaction
mix over a large number of wells, so that each well contains
a single copy or no copies of the target region.15 Based on
the assumption of Poisson distribution of copies, the num-
ber of template copies originally present in the sample can
be recalculated from the number of wells in which amplifi-
cation has successfully occurred. dPCR was performed on
a QuantStudioTM 3D Digital PCR System (Life Technolo-
gies, Carlsbad, CA, USA). We prepared 20 lL reaction
mixes containing 9 lL 1X QuantStudioTM 3D digital PCR
Master Mix (Life Technologies), 2 lL of 20X Sybr dye in
TE buffer, 50 ng cDNA in total reaction, 200 nmol/L of
specific primers, and 6.3 lL of nuclease-free water (Qia-
gen, Germantown, MD, USA). We loaded 14.5 lL of the
reaction mixture onto a QuantStudioTM 3D digital PCR
20 K chip (Life Technologies) using an automatic chip loa-
der (Life Technologies) according to manufacturer’s
instructions. The chip is divided into 20,000 consistently
sized reaction wells in which the nucleic acid mixture was
randomly divided. Loaded chips underwent thermocycling
on the Gene Amp 9700 PCR system under following con-
ditions: 96°C for 10 min, 45 cycles of 60°C for 2 min, and
at 98°C for 30 sec, followed by a final extension step at
60°C for 2 min. After thermocycling, the chips were
imaged on a QuantStudioTM 3D instrument, which assesses
raw data and calculates the estimated concentration of the
nucleic acid sequence targeted by the FAMTM dye labeled
probes by Poisson distribution.16
RT-PCR
RNA was isolated using an RNeasy Lipid Tissue Mini Kit
(74804, Qiagen) from parietal cortex. PSEN2 levels (total,
exon 6 deletion [PS2V], and partial intronic retention
[+77 bp]) were measured in a QuantStudio version 3 real-
time PCR system (Thermo Fisher Scientific, Waltham,
MA, USA) and normalized to a standard curve generated
using cloned vectors DNA containing the wild-type, PS2V,
and +77 bp-specific PSEN2 cDNAs. Assay on Demand
(Applied Biosystems) kits were employed to measure
Notch1 (Hs01062014_m1), APP (Hs00169098_m1), Hes1
(Hs00172878_m1), and ACTB (Hs99999903_m1) by real-
time PCR. Fold changes were calculated using the DD-CT
method against beta-actin housekeeping gene.
Western blot analysis
Human fibroblasts were passaged in fibroblast culture med-
ium and lysed in cell lysis buffer (Cell Signaling Technol-
ogy, Danvers, MA) containing protease inhibitors and
separated by sodiumdodecyl sulfate (SDS)–polyacrylamide
gel electrophoresis using b-mercaptoethanol (Bio-Rad Lab-
oratories, Hercules, CA), 4–12% Bis-Tris gradient gels
(Invitrogen/Life Technologies, Carlsbad, CA), and 3-(N-
morpholino)-propanesulfonic acid–sodiumdodecyl sulfate
buffer (Life Technologies). Proteins were transferred to a
PVDF membrane (Bio-Rad). Membranes were exposed to
primary anti-PS2 C-terminal (EP1515Y, Abcam, Cam-
bridge, MA at 1:4000) and mouse anti-b-actin (Sigma-
Aldrich at 1:200,000) overnight at 4°C, then exposed to the
appropriate HRP-conjugated secondary antibody:donkey
anti-rabbit (GE Healthcare, Piscataway, NJ at 1:1000) or
sheep-anti-mouse (GE Healthcare at 1:2000) for 1 h at
room temperature. Proteins were visualized with enhanced
chemiluminescence (Pierce/ThermoFisher, Rockford, IL).
Quantification of protein was performed employing ImageJ
software (National Institutes of Health, Bethesda, MD).
Brain protein lysates were prepared by sonicating fro-
zen brain tissue in SDS sample buffer (2% SDS, 10%
glycerol, 50 mmol/L Tris-Cl, pH 6.8) on ice. Western blot
analysis was performed under denaturing conditions
using 4–15% gradient or 10% polyacrylamide gels (Bio-
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Rad, Hercules, CA). Proteins were electroblotted onto a
PVDF membrane (Bio-Rad), fixed with 0.4%
paraformaldehyde for 30 min, and blocked in 5% nonfat
dry milk, 0.1% Tween 20, and 0.05% thimerosal before
overnight incubation at 4°C with primary antibody.
Membranes were incubated with appropriate HRP-conju-
gated secondary antibody (1:5000; GE Healthcare,
Pittsburgh, PA). Membranes were developed with Clarity
Western ECL substrate (Bio-Rad) and exposed to Hyper-
film ECL (GE Healthcare).
Amyloid beta peptide analysis
Human fibroblasts were plated a density of 2 9 104 cells
per well of a 96-well tissue culture-treated plate in tripli-
cate. Conditioned media was collected at 24-, 48-, and 72-h
time points and analyzed for levels of Ab1–38, Ab1–40, and
Ab1–42 using the human (6E10) Abeta Triplex Kit (Meso
Scale Discovery, Rockville, MD). Cells were subsequently
lysed in the well with cell lysis buffer (Cell Signaling Tech-
nology) containing protease inhibitors. Total protein con-
centration for each well was determined using the Pierce
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL)




The patient was first evaluated in an emergency department
at age 51 after concerned neighbors noted her inability to
care for herself while living alone. At time of presentation,
there was history of an “unspecified psychiatric disorder”
with reports of a several year history of persecutory delu-
sions. Neurological examination demonstrated poor recall,
evidence of apraxia, difficulty following commands, perse-
veration, and disinhibition. There were no focal neurologi-
cal findings. MRI showed moderate to severe cortical
atrophy and severe white matter disease. At age 53, exami-
nation by a University of Washington Alzheimer Disease
Research Center (UW ADRC) neurologist (J. L.) showed
that she was unable to stand without assistance, had snout
and palmomental reflexes, was nearly mute; she was given a
diagnosis of dementia of unclear etiology. Family history
was significant only for a mother reportedly diagnosed with
AD (though details were not known).
Family B: proband
The patient was referred to the UW Neurogenetics clinic
with a diagnosis of early-onset AD and had been previ-
ously reported by our group.9 She had onset of cognitive
impairment by age 50 and was diagnosed with AD at age
58. She had undergone a fluorodeoxyglucose-positron
emission tomography (FDG-PET) brain scan, and neu-
ropsychological examination supported a diagnosis of
dementia due to AD. Given her early age of onset, genetic
testing was pursued and she was found to carry PSEN2
K115Efs*11.9 In addition to early-onset AD, she was later
diagnosed with breast cancer after the original report and
underwent chemotherapy. Her subsequent course was
consistent with progressive memory-predominant cogni-
tive decline; she passed at age 68.
Family B: case 2
The patient was a 42-year-old right-handed Caucasian
woman and daughter of the proband. She presented to
the UW ADRC endorsing subjective mild memory con-
cerns beginning 2 years prior. She had observed difficulty
recalling the exact date of her child’s birthday. She fre-
quently forgot details of significant events and needed to
refer to recipes she previously knew well. She had no sig-
nificant medical history. Her neurological examination
was unremarkable.
Cognitive testing
The patient completed standardized cognitive testing
(National Alzheimer Coordinating Center’s Uniform
Data Set 3 and site-specific supplemental measures) at
both her initial and annual follow-up visits. Results
indicated mild but significant deficits in contextual ver-
bal memory coupled with subtler object naming diffi-
culty and mild variability in aspects of processing speed
(Table 1). Repeat evaluation demonstrated continued
memory impairment but did not yield clear evidence of
progressive deterioration over time. Her neurocognitive
profile was deemed to be consistent with amnestic mild
cognitive impairment coupled with possible early lan-
guage changes, concerning for underlying Alzheimer’s
etiology.
Molecular imaging
The [18F] florbetapir PET brain scan was negative; the lack
of cortical tracer uptake was not consistent with the pres-
ence of moderate to frequent amyloid neuritic plaques.
Pathology
Family A: proband
The postmortem interval was 4 h. The fresh brain weighed
1250 g. There was mild frontoparietal and moderate
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temporal atrophy, as well as mild ventricular dilatation.
There was no atrophy of the amygdala or hippocampus.
Amyloid beta plaques were present in the isocortex (frontal
lobe, cingulate gyrus, gyrus rectus, superior, middle, and
inferior temporal lobe, inferior parietal lobe, and calcarine
cortex), caudate nucleus, putamen, amygdala, hypothalamic
nuclei, parahippocampal gyrus, thalamus, hippocampus,
entorhinal and transentorhinal cortices, basal ganglia, and
cerebellum, indicating a Thal phase 5 of 5. Neuritic plaques
were frequent in the neocortex by CERAD criteria.12 Neu-
rofibrillary tangles were present in the CA1 in the hip-
pocampus, subiculum, entorhinal and transentorhinal
cortices, insular cortex and medial temporal cortices, basal
ganglia, amygdala, locus ceruleus, and isocortex, indicating
a Braak stage VI of VI. High PHF-tau burden was present
in the insular cortex, medial temporal cortex, and amygdala.
These findings lead to a diagnosis of AD neuropathologic
change: HIGH (A3, B3, C3; see Fig. 1). There was severe
cerebral amyloid angiopathy without histopathological evi-
dence of microvascular disease. Lewy bodies and pTDP43
pathologies were not identified.
Family B: proband
The postmortem interval was 10.2 h. The fresh brain
weighed 954 g. The external examination of the brain
showed moderate cortical atrophy involving the frontal
and temporal lobes and mild cortical atrophy involving
the parietal lobes. Amyloid beta deposition was present
in the isocortex, caudate nucleus, putamen, hippocam-
pus, parahippocampal gyrus, midbrain, and cerebellum,
indicating a Thal phase 5 of 5. Neuritic plaques were fre-
quent in the neocortex by CERAD criteria. Neurofibril-
lary tangles were present in the CA1 in hippocampus,
subiculum, entorhinal and transentorhinal cortices, insu-
lar cortex and medial temporal cortices, basal ganglia
amygdala, locus ceruleus, and isocortex, indicating a
Braak stage VI of VI. These findings lead to a diagnosis
of AD neuropathologic change: HIGH (A3, B3, C3; see
Fig. 1). Lewy bodies and pTDP43 pathologies were not
identified.
Both patients show diffuse Neurofibrillary tangles depo-
sition and dense tau neurites in the dentate gyrus, hilus,
and cornu ammonis. The involvement was considered to
be similar between the hippocampus and cortex. In sum-
mary, both patients showed severe and impressive patho-
logic changes of AD without histopathological evidence of
microvascular disease.
Identification of the PSEN2 two base-pair
deletion
Genetic sequencing
We sequenced the exome of Family A Proband and 134
additional unrelated individuals with early-onset and/or
Table 1. Summary of neuropsychological measures at baseline for
Family B: case 2.
Age at testing 42
WTAR estimate of premorbid intelligence 31 (39th %ile)
MoCA (max = 30) 25 (12th %ile)
CDR total 0.5
CDR sum of boxes 0.5
Learning and memory
Benson Complex Figure Delayed Recall
(max = 17); recognition
13; yes (46th %ile)
Craft Story 21
Immediate recall –verbatim (max = 44) 16 (7th %ile)
Immediate recall –paraphrased (max = 25) 13 (10th %ile)
Delayed recall –verbatim (max = 44) 8 (1st %ile)
Delayed recall –paraphrased (max = 25) 8 (1st %ile)
Rey Auditory Verbal Learning Test
Trial 1 total correct (max = 15) 5 (17th %ile)
Trial 5 total correct (max = 15) 14 (81st %ile)
Trials 1–5 total correct (max = 75) 51 (49th %ile)
Trial B total correct (max = 15) 7 (68th %ile)
Trial 6 total correct (max = 15) 11 (59th %ile)
200 free recall (max = 15) 9 (33rd %ile)
200 recognition hits (max = 15) 13 (23rd %ile)
200 recognition false positives 2
Attention, processing speed, and executive functioning
Trail Making Part A 20″ (45th %ile)
Trail Making Part B 48″ (46th %ile)
Span of digits forward (max = 9) 7 (56th %ile)
Span of digits backward (max = 8) 7 (89th %ile)
Letter Number Sequencing (max = 21) 12 (75th %ile)
WAIS-R Digit Symbol (max = 93) 68 (85th %ile)
Stroop (Golden) Word; errors 92, 0 (19th %ile)
Stroop (Golden) Color; errors 81, 0 (61st %ile)
Stroop (Golden) Color-Word Interference;
errors
42, 1 (50th %ile)
Language functioning
Repetition (max = 2) 1
Multilingual naming test (max = 32) 28 (17th %ile)
FL verbal fluency (# words) 28 (38th %ile)
Animals/minute 28 (74th %ile)
Vegetables/minute 18 (52nd %ile)
Visuospatial functioning
Cube copy (max = 1) 0
Benson Complex Figure Copy (max = 17) 15 (26th %ile)
Benton Judgment of Line Orientation (15
item)
14 (80th %ile)
All scores represented as raw scores (percentile), with bold/italic text
indicating that performance in the low average or impaired range
compared to people of the same age, sex, and level of education.
Limitation of the adjusted normative data for UDS measures is the
small sample of same-aged subjects enrolled in NACC.
CDR, Clinical Demenita Rating; MoCA, Montreal Cognitive Assess-
ment; NACC, National Alzheimer’s Coordinating Center; UDS, Uni-
form Data Set; WTAR, Wechsler Test of Adult Reading.
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familial dementia with archived DNA. Initially, we ana-
lyzed the sequences of 38 key risk genes. The PSEN2
K115fs previously described in patient Family B Proband9
was found in Family A Proband but not in the other 134
samples. The two base-pair deletion PSEN2 (NM_
000447.2): c.342_343delGA (p.Lys115GlufsX11), genomic
coordinates (b37): chr1:227071603 was confirmed using
Sanger sequencing. No clinically relevant variants were
found in the other 37 genes known to cause dementia or
a dementia-like phenotype. We analyzed the remainder of
the exome sequence data and did not identify any likely
pathogenic known causative variants.
Individual Family B Case 2 carries PSEN2 K115fs initially
identified in her mother (Family B Proband).9 We detected
PSEN2 K115fs by Sanger sequencing using specific primers
(see Table 2). We examined the exome sequence of Family
B Proband and found no pathogenic variants.
Although there is no known pedigree connection, it is
possible Families A and B are related by a common
ancestor. We compared the exome sequences of Family A
Proband and Family B Proband. Each patient carried
more than 100 rare variants, but only shared one: the
PSEN2 K115fs. Although this does not rule out distant
kinship, our analyses suggest that these families are not
related and the PSEN2 K115fs variants may have arisen as
separate events.
PSEN2 K115fs transcript is present
Early termination codon variants can be subject to non-
sense-mediated decay (NMD).18 To determine the relative
PSEN2 K115fs transcript levels, we used digital droplet
PCR. We observed wild-type PSEN2 transcript in two
independent wild-type controls but no variant-specific
transcript (Fig. 2C). In PSEN2 K115fs patient fibrob-
lasts, the mutant transcript is expressed at decreased
levels compared to wild-type transcript suggesting that
transcript instability, reduced transcription, or target-
ing by NMD contributes to reduced levels of the variant
allele.
PS2 protein expression in patient fibroblasts
To determine the impact of PSEN2 K115fs on the expres-
sion of wild-type PS2, we analyzed patient fibroblast
lysates by western blot, probing for the N-terminal and
C-terminal PS2 post-endoproteolytic fragments. We
detected only the wild-type copy of PS2 amino terminus
fragment (Fig. 2D), which was significantly decreased in
the PSEN2 K115fs fibroblasts compared to control
(Fig 2E). While we predicted that the mutant transcript
would result in a smaller truncated protein which could
be identifiable by the N-terminal antibody, it was not
detectable when using commercial N-terminus PS2 anti-
bodies targeting the wild-type protein (Fig. 2B and D;
Fig. S1). The PS2 C-terminal fragment expression is also
significantly reduced in PSEN2 K115fs cells compared to
wild-type controls, suggesting that in PSEN2 K115fs cells,
levels of wild-type PS2 protein are decreased, consistent
with decreased wild-type transcript or altered stability of




Forward (with M13 tail) TGTAAAACGACGGCCAGTCATCCAGCTCCAAATCTTCTCTACT
Reverse (with M13 tail) CAGGAAACAGCTATGACCCTGGTGTGGAGCTGCAGGTAC
Digital droplet PCR
PSEN2 WT, sense (50?30) TGTGCGCTTCTACACAGAGAAGAAT
PSEN2 WT, anti-sense (50?30) CGAGGGTGTGTCCTCAGTGAA
PSEN2 K115Efs*11, sense (50?30) TGTGCGCTTCTACACAGAAGAAT
PSEN2 K115Efs*11, anti-sense (50?30) CGAGGGTGTGTCCTCAGTGAA
Figure 1. Family A: Proband; Neuropathologic staging. (A–C) IHC stain for PHF-tau showing increased Tau burden characterized by neurofibrillary
tangles and Tau neurites. (A) Frontal lobe (409). (B) Hilus (409). (C) Visual cortex (409). (D–F) IHC for b-amyloid demonstrates widespread amyloid
plaques. (D) Frontal lobe (1.259). (E) Putamen (209). (F) Cerebellum (49). (G) Bielschowsky stain of frontal lobe (109) showing frequent neuritic
plaques. (H) H&E/LFB stain of CA1 region (609). Black open arrows – neurofibrillary tangles, black closed arrow – granulovacuolar degeneration,
and white open arrow – Hirano body. (I) H&E/LFB of frontal lobe (1.259) showing diffuse white matter involvement. Family B: Proband;
Neuropathologic staging. (A–C) IHC stain for PHF-tau showing increased Tau burden characterized by neurofibrillary tangles and Tau neurites. (A)
Frontal lobe (409). (B) Hilus (409). (C) Visual cortex (409). (D–F) IHC for b-amyloid demonstrates widespread amyloid plaques. (D) Frontal lobe
(1.259). (E) Putamen (209). (F) Cerebellum (49). Black open arrow – amyloid angiopathy. (G) Bielschowsky stain of frontal lobe (109) showing
frequent neuritic plaques. (H) H&E/LFB stain of CA1 region (409). Black open arrows – neurofibrillary tangles, black closed arrow – granulovacuolar
degeneration, and white open arrow – “ghost tangle.” (I) H&E/LFB of frontal lobe (1.259) showing that the white matter is much less affected as
compared to the first case. IHC, Immunohistochemical; PHF-tau, paired helical filament tau; H&E/LFB, hematoxylin and eosin with Luxol fast blue.
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Figure 2. Fibroblast PSEN2 sequencing, transcript analysis, and protein expression. (A) Chromatogram from Sanger sequencing of Family B: Case
2. Top panel, control fibroblasts; bottom panel, PSEN2 K115Efs*11 fibroblasts. Light blue highlights the bases prior to and including the two
base-pair GA deletion (underlined in control fibroblast sequence). (B) Illustration generated by Protter program simulation (http://wlab.ethz.ch/
protter/start/) to demonstrate the consequences of frameshift and premature termination codon in PSEN2 K115Efs*11 compared to wild-type
PS2. Dark green indicates frameshift. (C) Values and confidence intervals derived from dPCR analysis of fibroblast cDNA to compare transcript
copy number between two independent wild-type cell lines and PSEN2 K115Efs*11. (D) Western blot comparing wild-type PS2N- and C-terminal
fragment expression with PSEN2 K115Efs*11; note the absence of signal in the expected range for a truncated protein due to PSEN2
K115Efs*11. (E) Quantification of both N- and C-terminal PS2 fragments. Unpaired t-test: P = 0.0008 (C-terminus); N-terminus P < 0.0001.
Number of replicated experiments: n = 4. PSEN2, presenilin 1; dPCR, digital polymerase chain reaction. ***P < 0.001 and ****P < 0.0001.
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PSEN2 K115fs enzymatic activity
Due to the decrease in expression of PS2 components
necessary for enzymatic activity, we expected that c-
secretase enzymatic function would be decreased as well.
To probe this function we measured the c-secretase
enzyme cleavage products of the well-known substrate,
APP. In order to determine whether PSEN2 K115fs
fibroblasts exhibit a decreased ability to process APP, we
measured the level of secreted Ab from control fibrob-
lasts and PSEN2 K115fs fibroblasts at three time points
(Fig. 3). In comparison to wild-type fibroblasts, PSEN2
K115fs fibroblasts secreted a decreased amount of Ab1–
40. Secreted Ab1–40 is known to be decreased in cells
expressing FAD-associated PSEN2 N141I, replicated
here as an additional control.19 Levels of the other Ab
peptide species Ab1–38 and Ab1–42 were below the limits
of detection for this assay. To determine if the decrease
in Ab1–40 was more likely related to impaired cleavage
by PSEN2 K115fs rather than decreased substrate we
measured APP transcript by real-time-PCR (RT-PCR)
and by western blot, revealing similar levels of APP
between the PSEN2 variant and control (Fig. S2). In
addition, we assessed the impact of the PSEN2 K115fs
variant on endopeptidase cleavage of Notch1, which is
known to be impaired in cells expressing the canonical
PSEN2 N141I variant.19,20 Transcript levels of Hes1 are
an indicator of Notch intracellular domain release
following c-secretase cleavage of Notch1.21 We found
that PSEN2 K115fs fibroblasts have decreased Hes1
levels compared to control suggestive of impaired Notch
cleavage (Fig. S3). These data indicate that the PSEN2
K115fs variant alters the functional activity of PS2 simi-
lar to a known pathogenic variant in the presence of
two wild-type PSEN1 alleles.
Brain-enriched PS2 isoforms
Previous studies suggest that haploinsufficiency of PSEN1
is not sufficient to drive the molecular phenotypes of
AD.22 Furthermore, the overwhelming majority of mis-
sense variants and the notable paucity of haploinsuffi-
ciency variants linked to AD in either presenilin gene
suggests that PSEN2 K115fs-associated AD is possibly dri-
ven by expression of an aberrant transcriptional product
of PSEN2.3 While it is possible that a small amount of
the truncated protein may be responsible for driving the
disease, it is also possible that the frameshift may lead to
altered splicing of PSEN2.
A known PSEN2 splice isoform, PS2V, excludes PSEN2
exon 6 (previously referred to as exon 5 in original
reports) and leads to a frameshift of 10 amino acids fol-
lowed by a premature stop codon.23 The generation of
PS2V can be mediated in vitro by HMGA1 binding and
under hypoxic incubation conditions.23,24 Increased PS2V
transcript and protein product have been detected in the
Figure 3. Analysis of the products of APP cleavage by PS2. Secreted Ab1–40 from conditioned media collected from wild-type, PSEN2
K115Efs*11, or PSEN2 N141I fibroblasts was analyzed at three independent time points using Meso Scale Discovery Assay, (Rockville, MD) analysis
and normalized to protein concentration from each sample. Sidak statistical analyses: in comparison to WT at 24 h, P = 0.0059 (**) and
P = 0.0001 (***) for PSEN2 K115fs and PSEN1 N141I, respectively. At 48 h, P = 0.0005 (***) and P < 0.0001 (****) for PSEN2 K115fs and
PSEN1 N141I, respectively. At 72 h, P = 0.0405 (*) and P = 0.0015 (**) for PSEN2 K115fs and PSEN1 N141I, respectively. APP, amyloid precursor
protein; PSEN2, presenilin 1.
770 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Alternative Splicing in PSEN2 Associated With AD J. E. Braggin et al.
brains of patients with sporadic AD suggesting a possible
role in AD pathogenic processes.23,25 The mechanism by
which PS2V influences AD pathogenesis remains unclear
though its presence in AD brain raises the possibility
that altered splice forms of FAD genes may contribute to
AD pathogenesis. Several PS FAD-associated variants
also generate alternatively spliced isoforms, producing
unexpected products.26–29 Therefore, we sought to deter-
mine if PSEN2 K115fs transcript results in alternatively
spliced isoforms that could produce a novel deleterious
protein.
We designed primers to capture alternative splicing
that might occur between exons 5 and 7 (Fig. 4A;
Fig. S4), which would also capture loss of exon 6 (PS2V).
We amplified cDNA from wild-type PSEN2, PSEN2
K115fs, and PSEN2 N141I fibroblast RNA using primers
flanking exon 6. While a product of the expected size was
present, no alternative banding pattern was evident, sug-
gesting that alternative splicing is not robust at this
region in fibroblasts (Fig. 5).
To determine whether alternative splicing might occur at
this site in a more disease-relevant tissue, we isolated RNA
and generated cDNA from PSEN2 K115fs brain lysate. In
addition to the expected band, we found two additional
bands of both larger and smaller size than the original
band. Upon sequencing by TOPO cloning, we determined
that the larger band represents a 77 base-pair partial intro-
nic retention (Figs. 4A, 5). The smaller size band resulted
from the loss of exon 6, representing the PS2V isoform
(Figs. 4A, 5). Intriguingly, these alternative isoforms are
not PSEN2 K115fs patient specific. Using RT-PCR specific
for detection of the partial intronic retention isoform, we
determined that a small percentage of PSEN2 transcripts
spliced in this manner are present in both Sporadic AD
Figure 4. Consequences of alternative splicing. (A) Schematic demonstrating the predicted outcome of alternative splicing with or without the
presence of PSEN2 K115Efs*11. (B) PSEN2 K115Efs*11-specific predicted addition of 25 amino acids (consequence of 77 base-pair partial intronic
retention) or deletion of 48 amino acids (consequence of exon 6 exclusion) after the first PS2 transmembrane domain (generated with the Protter
program simulation, http://wlab.ethz.ch/protter/start/).46 Dark green indicates frameshift, while purple indicates the region of 25 inserted amino acids.
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(SAD) and Familial AD (FAD) brain lysate as well as in
control brain (Fig. 5). Of note, one SAD case with levels
of the 77 base-pair partial intronic retention transcript
similar to PSEN2 K115fs (Fig. 5, SAD II) had an early
age-of-onset at 50 years and was found to carry the
PSEN2 R62H variant previously suggested to be an age-of-
onset modifier.30
Upon analyzing the sequence surrounding the exon 6
splice acceptor site in a splice site prediction program
human splicing finder (http://www.umd.be/HSF3/), we
found that surprisingly, the site corresponding to a 77-
nucleotide insertion has a greater context score than the
canonical splice acceptor site. Thus, one or more pro-
teins involved in suppressing silencing likely prevent use
of the upstream splice acceptor. In the context of aging
or in the brain, the mechanism to prevent inclusion of
the upstream splice acceptor may be weakened over
time. By using RNA sequencing data deposited from the
Mount Sinai Brain Bank, we confirmed that 20 of 165
sequenced anterior frontal cortex samples had reads that
overlapped the upstream 77-nucleotide splice acceptor
site, providing independent verification of the utilization
of this splice site.
The deletion of two nucleotides in the PSEN2 K115fs
allele leads to expression of both the partial intronic
retention and PS2V transcripts, which enables return to
the original reading frame following a short frameshift.
The partial intronic retention is predicted to result in a
25-amino acid insertion into the loop between the first
and second transmembrane domains (Fig. 4B, Fig. S5).
Similarly, the exclusion of exon 6 (PS2V) isoform is pre-
dicted to return to the original reading frame after a short
frameshift, which would instead cause a 48-amino acid
deletion and predicted loss of the entire second trans-
membrane domain (Fig. 4B, Fig. S5). These altered tran-
scripts are predicted to be translated into full-length
proteins due to the presence of the two absent base pairs
of the PSEN2 K115fs allele.
Brain PS2 protein expression
Due to the predicted insertion or deletion of large peptide
sequences, either protein product generated from alterna-
tive PS2 isoforms may impact the structure and/or func-
tion of PSEN2 K115fs within the brain. Furthermore, the
presence of these alternative products may act in a domi-
nant-negative fashion against wild-type PS2. Therefore,
we sought to determine whether we could detect the pres-
ence of these protein products in brain lysate. While we
did not detect these alternative products by western blot
of PSEN2 K115fs brain lysate (Fig. 6), this could be due
to lack of antibody specificity, insufficient resolution due
to a size difference of 2–3kD, or low level of expression
due to low transcript abundance.
Figure 5. Alternative transcripts are present in brain-specific lysates. Top: PCR amplification of cDNA from brain lysates between exons 5 and 7
show two alternatively spliced products above and below a main PSEN2 band. Bottom: RT-PCR quantification of alternatively spliced products. RT-
PCR, real-time polymerase chain reaction; PSEN2, presenilin 1.
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Discussion
We report strong evidence supporting pathogenicity of a
two base-pair PSEN2 deletion variant in two individuals
with neuropathologically documented early-onset AD. The
majority of reported FAD-associated variants in the prese-
nilin genes are missense3 and hypothesized to process amy-
loid and other substrates abnormally.4 Our analysis of
fibroblast-secreted Ab data suggests that, like PSEN2
N141I, PSEN2 K115fs imparts a biochemical loss-of-func-
tion phenotype (Fig. 3). We have confirmed the presence
of the transcribed PSEN2 K115fs allele and demonstrate
that this pathogenic variant undergoes alternative splicing
detectable in brain using semiquantitative measures. The
alternative transcripts are predicted to generate structurally
and functionally altered PS2 protein products, which may
contribute to the development of AD. The proposed
pathogenic mechanism(s) leading to AD driven by PSEN
variants are complex31; our studies suggest at least three
mechanisms by which the molecular change in PSEN2
described here could lead to neural dysfunction.
1. Loss of normal PS2 function. The observed biochemi-
cal alterations noted in patient fibroblasts may be
explained by the decreased dose of wild-type PS2 protein.
Congruent with this model, wild-type PS2 expression is
significantly reduced by western blot (Fig. 2E). We
detected decreased levels of both N- and C-terminal frag-
ments in patient lysates, and a stronger impact on C-ter-
minus levels which may reflect differential stability or
susceptibility to degradation. Previous work has demon-
strated that PS fragments are rapidly degraded when not
incorporated into a heterodimer and thus alterations of
heterodimer or c-secretase complex stoichiometry in
PSEN2 variant cells may influence detectable levels of PS2
fragments.32
2. Expression of truncated PS2 protein: The loss of two
base pairs in PSEN2 K115fs would lead to a frameshift
followed by a premature stop codon. This transcript is
predicted to generate a severely truncated PS2 protein
product. In silico analyses suggest that the location of the
two base-pair deletion marks the transcript as a canonical
target for NMD because the premature stop codon
induced by the frameshift is located more than 50 nucleo-
tides upstream of a splice junction.18 We did detect the
PSEN2 K115fs allele (Fig. 2C) though whether the tran-
script is stable or escapes eventual NMD mediated degra-
dation was not assayed in these studies. If the shortened
transcript was expressed at low levels and translated, a
Figure 6. Western blot of brain lysates. Wild-type PS2 protein is detected by both N- and C-terminal antibodies.
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PSEN2 K115fs truncated protein would only retain one of
eight transmembrane domains, lacking both the endopro-
teolytic and catalytic sites of PS2 (Fig. 2B, Fig. S5). Simi-
larly, the known PS2 splice isoform PS2V, which excludes
PS2 exon 6, also leads to a frameshift followed by a pre-
mature stop codon.23 Because of the clear similarity
between PSEN2 K115fs and PS2V, it is possible that, like
PS2V, low-level truncated PSEN2 K115fs protein expres-
sion might be linked to disease. With commercial anti-
bodies, we were unable to detect expression of a
truncated PSEN2 K115fs fragment (Fig. 2D). It is possible
that a truncated peptide could be expressed below the
limit of detection by this assay or other mechanisms may
diminish the expression of the transcript product. As was
required for detection of the PS2V protein isoform, detec-
tion of the truncated PSEN2 K115fs may require creation
of a peptide-specific antibody.25
3. Expression of brain tissue enriched PS2 splice forms: We
hypothesized that alternative splicing may be responsible
for the generation of one or more novel, deleterious pro-
tein products. As previously discussed, PSEN2 is known to
undergo alternative splicing, generating the PS2V isoform
through exon 6 exclusion.23 Several pathogenic PSEN1
variants also employ alternative splicing, such as the muta-
tion of a splice donor site to generate alternative transcripts
as well as exon exclusion.27,28 Furthermore, global tran-
scriptomics studies have revealed that alternative splicing
occurs most often in brain tissue33,34; therefore, it is likely
that alternative splicing could impact several presenilin
variants in previously unexplored ways. To examine
whether PSEN2 K115fs generated alternatively spliced tran-
scripts, we PCR-amplified cDNA using primers upstream
and downstream of exon 6. While alternative splicing was
not detectable at this site in fibroblasts using semiquantita-
tive methods, we found a novel partial intronic retention
transcript as well as PS2V in brain lysate. These transcripts
were not unique to PSEN2 K115fs, as they were also found
in FAD, sporadic, and non-AD age-matched control brain
lysates. In silico, the aforementioned alternatively spliced
transcripts found in sporadic AD and non-AD control
would not be translated into full-length PS2 due to a fra-
meshift leading to a premature stop codon. Interestingly,
in the context of PSEN2 K115fs, both alternative tran-
scripts would return to the original reading frame. The
PSEN2 K115fs partial intronic retention transcript is pre-
dicted to express a 25-amino acid insertion after the first
transmembrane domain, while PS2V exon 6 loss is pre-
dicted to cause 48-amino acid loss and an entire trans-
membrane domain (Fig. 4B, Fig. S5). The expression of
either alternative protein was below the limit of detection
by western blot. This may be due to the low percentage or
instability of the proteins, additional undetected alternative
splicing downstream in the transcripts, or inability of the
antibody to recognize the altered protein products. These
alternative PS2 protein structures could impact substrate
processing, protein folding, subcellular localization, and c-
secretase complex formation in unanticipated ways. For
example, FAD-associated presenilin mutant proteins have
been demonstrated to act in a dominant-negative way by
heterooligomerizing with wild-type presenilin.35
Alternative splicing of AD risk genes in
sporadic AD
Alternative splicing of PSEN2 in the context of an AD-asso-
ciated variant could lead to the expression of deleterious
protein products. However, these alternative splicing events
are not unique to PSEN2 K115fs. Changes in neuronal
synaptic function during aging are linked to alternative
splicing and may also contribute to disease.36 Alternative
splicing confers transcriptomic and protein complexity to
brain tissue, increasing both with age and in AD.33,37,38 Sev-
eral groups have found that genes such as APP, Tau, APOE,
and ABCA7 can undergo alternative splicing, potentially
increasing risk for disease.38,39 Other splice machinery
alterations can impact APP processing of Ab indirectly
through alternative splice-driven changes in function, such
as transcription factors and regulators like RbFox1.38 Fra-
meshifted proteins resulting from acquired dinucleotide
deletions (DGA or DGU) in APP and Ubiquitin mRNA
have also been associated with SAD pathology and sug-
gested to contribute to AD pathogenesis.40,41 Thus, our
data complement the growing body of work suggesting that
alternative splicing or RNA editing in brain tissue may be a
relevant component of AD pathogenesis.
Protein products resulting from presenilin alternative
splicing could be responsible for contributing to AD.
Similar variants previously categorized as unknown signif-
icance due to unclear mechanisms may also induce or
undergo alternative splicing, and further study is merited
in these cases. Of note, a recent publication highlighted
the discovery of an additional PSEN2 frameshift variant
concluded to be of unknown significance found in two
individuals with AD. The identified one base-pair deletion
variant in PSEN2 was also found to generate altered splice
forms and resulted in decreased wild-type PS2 protein in
brain tissue.42 Characterizing the full variation in mecha-
nism through the study of noncanonical variants will aid
in understanding the mechanism of FAD as well as of
sporadic AD. Alternatively spliced products may impact
the molecular phenotypes of AD in vitro, such as the
secretion of Ab, phosphorylation of tau, electrophysiolog-
ical properties, or the susceptibility to hypoxia and/or
other environmental or aging-related insults.
Although the amyloid PET scan of Family B Case 2 did
not demonstrate the presence of moderate to severe
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cortical amyloid neuritic plaques, it is possible that this
individual does not yet have a burden of fibrillar amyloid
pathology that reaches the threshold of detection. Individ-
uals with symptomatic FAD lacking evidence of fibrillar
amyloid deposition on amyloid imaging have been
reported previously.43,44 Additionally, binding affinity of
amyloid radiotracers has been found to be variable for
different FAD-associated variants.45
Conclusion
Our study highlights the importance of considering the
impact of alternative splicing of PSEN and other AD-
related genes. Further studies to explore mechanistic
impact of mRNA and protein isoforms associated with
PSEN2 K115Efs*11 will benefit from extension to physio-
logically disease-relevant cell types. Our study highlights,
through the analyses of multiple tissue types, the com-
plexity of investigating PSEN variant mechanisms in AD.
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Figure S1. Location of epitopes for western blotting.
Figure S2. APP and Notch levels do not differ signifi-
cantly between control and PSEN2 K115fs fibroblasts.
Figure S3. Hes1 expression in fibroblasts with and with-
out Jagged stimulation of Notch.
Figure S4. Real-time PCR schematic.
Figure S5. Amino acid changes as a result of PSEN2 K115fs.
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